Clinical Trial

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2023 (before its estimated July 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label study to evaluate the safety and efficacy of C-CAR088 in patients with relapsed or refractory multiple myeloma. The phase Ib part of this study is to determine the recommended phase 2 dose (RP2D) of C-CAR088 in the targeted patient population.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-08-28; most recent amendment 2023-03-22.
Trial Details
NCT Number NCT05521802
Lead Sponsor Shanghai AbelZeta Ltd.
Conditions Multiple Myeloma
Enrollment 92 participants
Start Date 2022-11-11
Primary Completion 2024-07 (estimated)
Study Completion 2037-07 (estimated)
Updated on ClinicalTrials.gov 2023-03-24